Sana Total Assets vs Total Current Assets Analysis

SANA Stock  USD 2.78  0.23  9.02%   
Sana Biotechnology financial indicator trend analysis is much more than just breaking down Sana Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sana Biotechnology is a good investment. Please check the relationship between Sana Biotechnology Total Assets and its Total Current Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.

Total Assets vs Total Current Assets

Total Assets vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sana Biotechnology Total Assets account and Total Current Assets. At this time, the significance of the direction appears to have totally related.
The correlation between Sana Biotechnology's Total Assets and Total Current Assets is 0.99. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Sana Biotechnology, assuming nothing else is changed. The correlation between historical values of Sana Biotechnology's Total Assets and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Sana Biotechnology are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Assets i.e., Sana Biotechnology's Total Assets and Total Current Assets go up and down completely randomly.

Correlation Coefficient

0.99
Relationship DirectionPositive 
Relationship StrengthVery Strong

Total Assets

Total assets refers to the total amount of Sana Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sana Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.
Most indicators from Sana Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sana Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.As of November 29, 2024, Selling General Administrative is expected to decline to about 46.5 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 30.1 M
 2021 2022 2023 2024 (projected)
Total Operating Expenses356.9M272.6M294.9M249.3M
Cost Of Revenue17.9M27.7M30.9M16.6M

Sana Biotechnology fundamental ratios Correlations

0.930.920.580.960.360.97-0.55-0.80.790.850.990.920.870.97-0.220.610.930.850.690.580.940.991.00.980.81
0.931.00.790.810.610.94-0.27-0.860.810.630.910.970.940.89-0.180.310.940.90.420.790.950.920.920.880.94
0.921.00.780.810.60.95-0.28-0.870.830.640.910.960.930.89-0.150.320.940.920.420.780.960.920.910.880.94
0.580.790.780.380.920.590.2-0.60.520.130.570.840.860.62-0.36-0.290.560.69-0.181.00.630.580.580.510.83
0.960.810.810.380.190.93-0.69-0.770.810.930.960.810.780.92-0.140.760.860.820.820.380.90.940.960.950.71
0.360.610.60.920.190.420.42-0.590.46-0.060.360.670.720.39-0.09-0.490.350.59-0.40.920.470.360.360.280.74
0.970.940.950.590.930.42-0.44-0.910.890.780.970.90.90.89-0.060.550.930.910.640.590.990.940.950.910.89
-0.55-0.27-0.280.2-0.690.42-0.440.17-0.37-0.88-0.5-0.27-0.19-0.580.28-0.87-0.5-0.38-0.860.2-0.37-0.6-0.59-0.66-0.1
-0.8-0.86-0.87-0.6-0.77-0.59-0.910.17-0.93-0.6-0.82-0.8-0.85-0.71-0.27-0.31-0.8-0.9-0.4-0.6-0.93-0.76-0.78-0.72-0.91
0.790.810.830.520.810.460.89-0.37-0.930.690.80.750.830.70.130.40.790.960.490.520.920.760.780.720.9
0.850.630.640.130.93-0.060.78-0.88-0.60.690.810.610.550.83-0.10.870.790.690.910.130.730.860.870.90.48
0.990.910.910.570.960.360.97-0.5-0.820.80.810.910.880.94-0.180.610.890.830.690.570.950.960.970.940.81
0.920.970.960.840.810.670.9-0.27-0.80.750.610.910.970.93-0.330.260.850.870.370.840.90.910.920.880.91
0.870.940.930.860.780.720.9-0.19-0.850.830.550.880.970.85-0.270.190.790.910.30.860.910.840.860.790.96
0.970.890.890.620.920.390.89-0.58-0.710.70.830.940.930.85-0.370.550.890.820.630.620.860.990.990.990.75
-0.22-0.18-0.15-0.36-0.14-0.09-0.060.28-0.270.13-0.1-0.18-0.33-0.27-0.370.0-0.08-0.06-0.02-0.36-0.03-0.26-0.26-0.28-0.06
0.610.310.32-0.290.76-0.490.55-0.87-0.310.40.870.610.260.190.550.00.530.320.99-0.290.480.590.610.650.12
0.930.940.940.560.860.350.93-0.5-0.80.790.790.890.850.790.89-0.080.530.860.620.560.920.950.930.930.8
0.850.90.920.690.820.590.91-0.38-0.90.960.690.830.870.910.82-0.060.320.860.420.690.930.850.850.810.94
0.690.420.42-0.180.82-0.40.64-0.86-0.40.490.910.690.370.30.63-0.020.990.620.42-0.180.570.680.690.730.23
0.580.790.781.00.380.920.590.2-0.60.520.130.570.840.860.62-0.36-0.290.560.69-0.180.630.580.580.510.83
0.940.950.960.630.90.470.99-0.37-0.930.920.730.950.90.910.86-0.030.480.920.930.570.630.910.920.870.93
0.990.920.920.580.940.360.94-0.6-0.760.760.860.960.910.840.99-0.260.590.950.850.680.580.911.00.990.78
1.00.920.910.580.960.360.95-0.59-0.780.780.870.970.920.860.99-0.260.610.930.850.690.580.921.00.990.79
0.980.880.880.510.950.280.91-0.66-0.720.720.90.940.880.790.99-0.280.650.930.810.730.510.870.990.990.71
0.810.940.940.830.710.740.89-0.1-0.910.90.480.810.910.960.75-0.060.120.80.940.230.830.930.780.790.71
Click cells to compare fundamentals

Sana Biotechnology Account Relationship Matchups

Sana Biotechnology fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets415.7M730.3M1.1B822.7M565.3M677.9M
Other Current Liab18.0M21.8M78.7M83.9M47.2M46.0M
Total Current Liabilities19.8M31.5M99.2M111.5M64.5M60.2M
Total Stockholder Equity(142.5M)(421.2M)728.5M499.3M287.5M172.0M
Other Liab74.7M198.9M199.9M116.0M133.4M129.7M
Net Tangible Assets(342.4M)(621.0M)528.7M299.5M344.4M361.6M
Property Plant And Equipment Net69.3M109.9M161.8M159.4M145.6M118.5M
Net Debt(31.8M)(340.1M)(142.1M)(68.5M)(29.4M)(30.9M)
Retained Earnings(144.1M)(429.4M)(785.4M)(1.1B)(1.3B)(1.3B)
Accounts Payable0.02.3M2.2M2.9M4.1M2.1M
Cash80.0M412.0M253.0M176.8M133.5M199.1M
Non Current Assets Total271.4M345.8M571.3M378.3M351.8M352.1M
Non Currrent Assets Other2.3M2.3M13.8M9.0M6.4M6.3M
Other Assets2.3M2.3M13.8M9.0M10.4M6.3M
Cash And Short Term Investments139.0M412.0M746.9M434.0M205.2M360.7M
Short Term Investments59.0M253.5M298.0M247.2M71.7M68.1M
Liabilities And Stockholders Equity415.7M730.3M1.1B822.7M565.3M677.9M
Non Current Liabilities Total538.4M1.1B301.7M211.9M213.3M324.1M
Capital Lease Obligations48.2M71.9M110.9M108.3M104.1M81.3M
Other Current Assets5.3M12.4M14.2M20.5M8.3M11.5M
Other Stockholder Equity(415.8M)852.9M1.5B1.6B1.6B941.7M
Total Liab558.2M1.2B400.9M323.4M277.8M367.9M
Net Invested Capital(142.5M)(421.2M)728.5M499.3M287.5M172.0M
Property Plant And Equipment Gross69.3M109.9M180.6M193.4M187.4M135.9M
Total Current Assets144.3M384.5M558.1M444.4M213.5M325.9M
Accumulated Other Comprehensive Income26K30K(1.4M)(4.3M)(60K)(63K)
Capital Stock1K2K18K19K20K11K
Non Current Liabilities Other74.7M198.9M301.7M211.9M122.4M166.8M
Net Working Capital124.4M353.0M458.9M332.9M149.0M265.7M
Property Plant Equipment68.8M109.9M65.5M66.9M77.0M68.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.40)
Return On Assets
(0.31)
Return On Equity
(0.93)
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.